Skip to content

Investigating how a special super inductive magnetic device can help ease muscle pain caused by Myofasical Pain Ssyndrome (MPS).

Isolation effect of Functional Magnetic Stimulator (FMS) on Myofascial Pain Syndrome (MPS). - NIL

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/067997
Enrollment
54
Registered
2024-05-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M791- Myalgia

Interventions

Intervention1: Functional Magnetic Stimulator: For subjects receiving Functional Magnetic Stimulation: The super inductive stimulator (the BTL-6000 Super Inductive System, by BTL Industries Ltd.) will

Sponsors

School Of Physiotherapy Delhi Pharmaceutical Science And Research University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: In order to participate in the study, individuals must experience both an active trigger point in the upper trapezius muscle and mechanical pain in the cervical region that has lasted for less than three months. Additionally, the pain intensity in the neck and cervical regions should be moderate, ranging from 3 to 8 on a Visual Analogue Scale (VAS) taken within the past 30 days, and the Neck Disability Index score should fall between 15 and 34 (inclusive).

Exclusion criteria

Exclusion criteria: Individuals with the following conditions will be excluded from the study: radicular syndrome (pain radiating down the arm), whiplash injury, or any diagnosed cervical pathology like a herniated disc. Additionally, those currently receiving treatment for neck or shoulder pain, using pain medication (analgesics, anti-inflammatory drugs, muscle relaxants), anticoagulant medications, or having a history of psychological/psychiatric conditions, active cancer, or who have undergone invasive spinal procedures within the last 4-6 months will not be eligible to participate.

Design outcomes

Primary

MeasureTime frame
Reduce pain and improvement in range of motion.Timepoint: Baseline After 3 weeks

Secondary

MeasureTime frame
Improvement in functional mobility.Timepoint: Baseline After 3 weeks

Countries

India

Contacts

Public ContactDr. Shilpa Jain

Delhi Pharmaceutical Science And Research University

shreyamishra988@gmail.com7060443388

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026